Since preclinical models demonstrated that recombinant TRAIL has potent anti-tumor activity without exhibiting systemic cytotoxicity [39], DR4 and DR5 were postulated as potential targets for future cancer therapeutics. This evidence concerns the gene TNFRSF10A and neoplasm.